Cd86 - CD86 molecule Gene

Also Known as B7-2

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 56822

Summary

Enables signaling receptor binding activity. Involved in several processes, including defense response to Other organism; negative regulation of T cell anergy; and positive regulation of activated T cell proliferation. Located in cell surface. Used to study adult T-cell leukemia and bronchiolitis obliterans. Biomarker of asthma; corneal disease; middle cerebral artery infarction; and orchitis. Human ortholog(s) of this gene implicated in several diseases, including Henoch-Schoenlein purpura; autoimmune disease (multiple); chronic lymphocytic leukemia; chronic obstructive pulmonary disease; and systemic scleroderma. Orthologous to human CD86 (CD86 molecule). [provided by Alliance of Genome Resources, Apr 2022]

Cd86 Products (1)

mRNA Protein Name
NM_020081.2 NP_064466.1 T-lymphocyte activation antigen CD86 precursor

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence Références Source
enables signaling receptor binding IPI
IPI: Inferred from physical interaction
17289805 RGD
Biological Process GO Annotation Evidence Références Source
involved in T cell proliferation involved in immune response IEP
IEP: Inferred from expression pattern
20500684 RGD
involved in cellular response to cytokine stimulus IEP
IEP: Inferred from expression pattern
19642897 RGD
involved in cellular response to lipopolysaccharide IEP
IEP: Inferred from expression pattern
21039614 RGD
involved in cellular response to metal ion IEP
IEP: Inferred from expression pattern
19653805 RGD
involved in defense response to virus IEP
IEP: Inferred from expression pattern
20603637 RGD
involved in myeloid dendritic cell differentiation IEP
IEP: Inferred from expression pattern
21039614 RGD
involved in negative regulation of T cell anergy IMP
IMP: Inferred from mutant phenotype
18424705 RGD
involved in positive regulation of T cell proliferation IMP
IMP: Inferred from mutant phenotype
19107191 RGD
involved in positive regulation of activated T cell proliferation IDA
IDA: Inferred from direct assay
9237108 RGD
involved in response to lipopolysaccharide IEP
IEP: Inferred from expression pattern
17935670 RGD
involved in response to type II interferon IEP
IEP: Inferred from expression pattern
16839612 RGD
involved in response to xenobiotic stimulus IEP
IEP: Inferred from expression pattern
18704298 RGD
involved in response to yeast IEP
IEP: Inferred from expression pattern
19494083 RGD
Cellular Component GO Annotation Evidence Références Source
located in cell surface IDA
IDA: Inferred from direct assay
9237108 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

T-lymphocyte activation antigen CD86

  • cd86 antigen

  • membrane glycoprotein

Recombinant Cd86 Proteins

Cat. No. Nom du produit Accession Pureté
HY-P7636 B7-2/CD86 Protein, Rat (HEK293, His) O35531 (V29-K247) ≥ 95%, as determined by reducing SDS-PAGE.

Related Agents

  • Clinical Phase
  • Pre-clinical Phase

Clinical Phase

Bioactive Molecules (5)
Cat. No. Nom du produit Effect
Pureté Phase
HY-N6664 Gum arabic / Phase 3
HY-115870 AZD8154 Inhibitor 99.88% Phase 2
HY-141677A INCB059872 dihydrochloride Inhibitor 99.64% Phase 2
HY-141677C INCB059872 TFA Inhibitor / Phase 2
HY-W016773 1,10-Decanediol 99.95% Phase 1
Inhibitory Antibodies (7)
Cat. No. Nom du produit Effect
Pureté Phase
HY-P991424 GSK2618960 Inhibitor 95.66% Phase 2
HY-P99821 Ravagalimab Inhibitor 99.31% Phase 2
HY-P99809 Quavonlimab Inhibitor ≥99.0% Phase 2
HY-P991566 KD6001 Inhibitor / Phase 2
HY-P991952 ADU-1604 Inhibitor / Phase 1
HY-P991961 REGN4659 Inhibitor / Phase 1
HY-P991366 IBI-397 Inhibitor / Phase 1

Pre-clinical Phase

Bioactive Molecules (29)
Cat. No. Nom du produit
Effect
Pureté
Rare Diseases
HY-148980A Polyinosinic acid sodium 91.5% Unkown
HY-150749A ODN D-SL03 sodium 98.57% Unkown
HY-163962 L18I 99.89% Unkown
HY-W722277A LCC-12 formate Inhibitor 99.90% Unkown
HY-141677 INCB059872 Inhibitor 99.60% Unkown
HY-138794B XL177B 99.36% Unkown
HY-150749 ODN D-SL03 Inducer 99.82% Unkown
HY-N10116A Calamenene / Unkown
HY-148980 Polyinosinic acid / Unkown
HY-141677B INCB059872 tosylate Inhibitor / Unkown
HY-143410 Anti-inflammatory agent 16 Inhibitor / Unkown
HY-144675 LSD1-IN-13 Inhibitor / Unkown
HY-144675A LSD1-IN-13 hydrochloride Inhibitor / Unkown
HY-150740 ODN 21595 Inhibitor / Unkown
HY-152201 BTK-IN-18 Inhibitor / Unkown
HY-160227 ORN 06 Activator / Unkown
HY-161833 HSP90-IN-31 Inhibitor / Unkown
HY-169819 Calcium influx inducer compound 634 / Unkown
HY-170403 LSD1-IN-38 Inhibitor / Unkown
HY-173070 TLR7 agonist 29 / Unkown
HY-179336 TLR7/8 agonist 14 / Unkown
HY-181781 LSD1-IN-48 / Unkown
HY-RS02274 CD86 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-W016773S 1,10-Decanediol-d20 / Unkown
HY-150740A ODN 21595 sodium Inhibitor / Unkown
HY-168384 M04 / Unkown
HY-184441 CD28-IN-4 Inhibitor / Unkown
HY-RS16645 Cd86 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS23079 Cd86 Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
Inhibitory Antibodies (8)
Cat. No. Nom du produit
Effect
Pureté
Rare Diseases
HY-P990260 Anti-Mouse CD86/B7-2 Antibody (GL-1) Inhibitor 99.17% Unkown
HY-P990127 Anti-Mouse CD80/B7-1 Antibody (RM80) Inhibitor 95% Unkown
HY-P990261 Anti-Mouse CD83 Antibody (Michel-17) Inhibitor 98.722% Unkown
HY-P991759 Anti-Rat CD86 Antibody (OX-48) Inhibitor / Unkown
HY-P991777 Anti-Mouse CD86/B7-2 Antibody (2D10) Inhibitor / Unkown
HY-P991908 Anti-CD86 Antibody (3D1) / Unkown
HY-P991918 KHK2840 Agonist / Unkown
HY-P992408 MEDI-5083 / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Cd86 NCBI NCBI:942